Rezolute (RZLT) announced that enrollment is complete in the sunRIZE study, a global, Phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug for the treatment of hypoglycemia in patients with congenital HI. “The completion of enrollment in the sunRIZE study is a significant milestone for Rezolute and those affected by congenital hyperinsulinism,” said Brian Roberts, M.D., Chief Medical Officer at Rezolute. “This achievement brings us one step closer to potentially offering a new therapeutic option in a space where few exist. We are deeply grateful to the patients, families, and investigators who are helping to advance care in an area that has long been underserved, and we look forward to announcing topline data later this year.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute, Inc. (RZLT) Q3 Earnings Cheat Sheet
- Rezolute’s Financial Stability and Clinical Progress Drive Buy Rating Amid Promising Phase 3 Trials
- Rezolute’s Promising Market Position and Clinical Advancements Drive Buy Rating
- Rezolute’s Ersodetug Shows Promise in Phase 3 Trials for CHI, Reinforcing Buy Rating and $12 Price Target
- Optimistic Buy Rating for Rezolute Driven by Promising Ersodetug Developments and Strong Financial Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue